These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32239189)

  • 1. Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer.
    Zhao Z; Cai S; Wang Z
    JAMA Oncol; 2020 Jun; 6(6):932. PubMed ID: 32239189
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer-Reply.
    Tie J; Vogelstein B; Gibbs P
    JAMA Oncol; 2020 Jun; 6(6):932-933. PubMed ID: 32239186
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA).
    Verbus EA; Rossi AJ; Luna AJ; Iqbal A; Morris VK; Hernandez JM
    Ann Surg Oncol; 2021 Aug; 28(8):4095-4097. PubMed ID: 33999346
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant chemotherapy guided by circulating tumour DNA in stage II colon cancer.
    Hindson J
    Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):488. PubMed ID: 35773389
    [No Abstract]   [Full Text] [Related]  

  • 5. Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?
    Morris VK; George TJ
    Clin Cancer Res; 2022 Feb; 28(3):438-440. PubMed ID: 34848532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer.
    Akagündüz B; Guven DC; Ozer M; Okten IN; Atag E; Unek İT; Tatli AM; Karaoglu A
    J Geriatr Oncol; 2023 Mar; 14(2):101367. PubMed ID: 36038467
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant chemotherapy in colon cancer: state of the art and future perspectives.
    Iveson T
    Curr Opin Oncol; 2020 Jul; 32(4):370-376. PubMed ID: 32541327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
    Auclin E; Zaanan A; Vernerey D; Douard R; Gallois C; Laurent-Puig P; Bonnetain F; Taieb J
    Ann Oncol; 2017 May; 28(5):958-968. PubMed ID: 28453690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant colon cancer chemotherapy: where we are and where we'll go.
    Lombardi L; Morelli F; Cinieri S; Santini D; Silvestris N; Fazio N; Orlando L; Tonini G; Colucci G; Maiello E
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S34-41. PubMed ID: 21129608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer.
    Otsuka M
    N Engl J Med; 2022 Aug; 387(8):759-760. PubMed ID: 36001721
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer.
    Hindié E
    N Engl J Med; 2022 Aug; 387(8):759. PubMed ID: 36001720
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer. Reply.
    Tie J; Lo SN; Gibbs P
    N Engl J Med; 2022 Aug; 387(8):760. PubMed ID: 36001722
    [No Abstract]   [Full Text] [Related]  

  • 16. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
    Hornberger J; Lyman GH; Chien R; Meropol NJ
    Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
    Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers.
    Westra JL; Plukker JT; Buys CH; Hofstra RM
    Clin Colorectal Cancer; 2004 Nov; 4(4):252-9. PubMed ID: 15555207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
    Sveen A; Nesbakken A; Ågesen TH; Guren MG; Tveit KM; Skotheim RI; Lothe RA
    Clin Cancer Res; 2013 Dec; 19(24):6669-77. PubMed ID: 24166914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.